Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies (Q33893704)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q102148850)
(Q114341073)
(P304) 88-94
(P407) (Q1860)
(P433) 1
(P478) 31
(P577) Monday, October 8, 2012
(P921) (Q5984881)
(P1433) (Q400292)
(P1476) "Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies" (language: en)
(P2093) Joseph J Buggy
Jeff P Sharman
Sonali M Smith
Thomas E Boyd
Barbara Grant
Kathryn S Kolibaba
Richard R Furman
Sara Rodriguez
Betty Y Chang
Juthamas Sukbuntherng
Ahmed Hamdy
Eric Hedrick
Nathan H Fowler
(P2860) (Q34037828)
(Q34249777)
(Q34029869)
(Q37936211)
(Q34542102)
(Q24633214)
(Q28279743)
(Q24613755)
(Q24599100)
(Q37614547)
(Q37028635)
(Q37504699)
(Q37419369)
(Q36117384)
(Q24616084)
(Q42742097)
(Q40284461)
(Q36085626)
(Q30164032)
(Q35667038)
(Q35666655)
(Q35077432)
(Q35014068)
(Q34303128)
(Q37305443)
(Q40019232)
(Q24564184)
(Q47582438)
(P4510) (Q112270642)
other details
description scientific article

External Links